

Resource Summary Report

Generated by [NIF](#) on Sep 9, 2026

HEY A8

RRID:CVCL_8878

Type: Cell Line

Proper Citation

RRID:CVCL_8878

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_8878

Proper Citation: RRID:CVCL_8878

Description: Cell line HEY A8 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: High grade ovarian serous adenocarcinoma

Defining Citation: [PMID:2394835](#), [PMID:22460905](#), [PMID:22710073](#), [PMID:23839242](#), [PMID:25984343](#), [PMID:27235858](#), [PMID:27561551](#), [PMID:28196595](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:31978347](#)

Comments: Population: Caucasian., Part of: MD Anderson Cell Lines Project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: HEY A8

Synonyms: HEY-A8, Hey-A8, Hey A8, HEYA8, HeyA8, Heya8

Cross References: BTO:BTO_0006454, ArrayExpress:E-MTAB-2770, BioGRID_ORCS_Cell_line:715, BioSample:SAMN10988247, cancercellines:CVCL_8878, Cell_Model_Passport:SIDM01215, Cosmic:1305329, DepMap:ACH-000542, GEO:GSM851918, GEO:GSM887080, GEO:GSM888150, IARC_TP53:30038, LiGeA:CCLE_702, Pharmacodb:HeyA8_542_2019, PRIDE:PXD003668, Progenetix:CVCL_8878, Wikidata:Q54883213

ID: CVCL_8878

Hierarchy: cvcl_0297

Record Creation Time: 20220427T220340+0000

Record Last Update: 20260905T180301+0000

Ratings and Alerts

No rating or validation information has been found for HEY A8.

No alerts have been found for HEY A8.

Data and Source Information

Source: [CelloSaurus](#)

Usage and Citation Metrics

We found 126 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Li Q, et al. (2026) KPNA2 Drives Immunosuppression in Ovarian Cancer via CCL2/CCR2-Dependent MDSC Recruitment. Cancer science.

Santander GN, et al. (2026) Framework for evaluating in vitro vasculogenic mimicry using structural and metabolic parameters. Cell reports methods, 101515.

Tan GYT, et al. (2026) BMAL2 is a druggable target for ovarian clear cell carcinoma (OCCC). EMBO molecular medicine, 18(5), 1933.

Borrelli MJ, et al. (2025) Spatiotemporal analysis of ratiometric biosensors in live multicellular spheroids using SPoRTS. Cell reports methods, 5(2), 100987.

Xiong X, et al. (2025) IGF2BP2 promotes malignant progression of ovarian cancer by regulating protein synthesis through liquid-liquid phase separation. Cell reports, 44(11), 116511.

Bayraktar E, et al. (2025) Epigenetic modulation of BARD1 to enhance anti-VEGF therapy. Cell reports. Medicine, 6(9), 102329.

Ma J, et al. (2025) Machine learning-based development of a cytotoxicity prediction model for NK cell therapy in cancers. Cellular oncology (Dordrecht, Netherlands), 48(6), 1837.

Zhang S, et al. (2025) Vertical inhibition of p110 α /AKT and N-cadherin enhances treatment efficacy in PIK3CA-aberrated ovarian cancer cells. Molecular oncology, 19(4), 1132.

Plesselova S, et al. (2025) Recapitulating physiologically relevant oxygen levels and extracellular matrix remodeling in patient-derived tumor-immune tunable models reveal targeting opportunities for immunologically cold high-grade serous tumors. *bioRxiv : the preprint server for biology*.

Lee YY, et al. (2024) The anti-tumor effects of AZD4547 on ovarian cancer cells: differential responses based on c-Met and FGF19/FGFR4 expression. *Cancer cell international*, 24(1), 43.

Wang L, et al. (2023) RBM4 regulates cellular senescence via miR1244/SERPINE1 axis. *Cell death & disease*, 14(1), 27.

Shin YB, et al. (2023) Anticancer Evaluation of Methoxy Poly(Ethylene Glycol)-b-Poly(Caprolactone) Polymeric Micelles Encapsulating Fenbendazole and Rapamycin in Ovarian Cancer. *International journal of nanomedicine*, 18, 2209.

Jin CE, et al. (2023) Synergistic Encapsulation of Paclitaxel and Sorafenib by Methoxy Poly(Ethylene Glycol)-b-Poly(Caprolactone) Polymeric Micelles for Ovarian Cancer Therapy. *Pharmaceutics*, 15(4).

Chen PM, et al. (2023) Actin-like Protein 6A Expression Correlates with Cancer Stem Cell-like Features and Poor Prognosis in Ovarian Cancer. *International journal of molecular sciences*, 24(3).

Yeo XH, et al. (2023) The effect of inhibition of receptor tyrosine kinase AXL on DNA damage response in ovarian cancer. *Communications biology*, 6(1), 660.

Martell E, et al. (2023) Metabolism-based targeting of MYC via MPC-SOD2 axis-mediated oxidation promotes cellular differentiation in group 3 medulloblastoma. *Nature communications*, 14(1), 2502.

Wang L, et al. (2023) Folate receptor targeted nanoparticles containing niraparib and doxorubicin as a potential candidate for the treatment of high grade serous ovarian cancer. *Scientific reports*, 13(1), 3226.

Tang B, et al. (2023) Combined treatment of disulfiram with PARP inhibitors suppresses ovarian cancer. *Frontiers in oncology*, 13, 1154073.

Young KM, et al. (2023) Correlating mechanical and gene expression data on the single cell level to investigate metastatic phenotypes. *iScience*, 26(4), 106393.

Jiang W, et al. (2023) A NOTCH1 Mutation Found in a Newly Established Ovarian Cancer Cell Line (FDOVL) Promotes Lymph Node Metastasis in Ovarian Cancer. *International journal of molecular sciences*, 24(6).